SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD FEB 05
MCX SILVER MAR 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD FEB 05
MCX SILVER MAR 05
MCX CRUDEOIL FEB 19
MCX NATURALGAS JAN 25
USD/INR
EUR/INR
GBP/INR
JPY/INR

Christopher Wood remains bullish on Indian markets despite run-up; prefers real-estate sector

Global Markets: Asia shares pare losses as China economy rebounds

Oil prices extend gains after US inventory drop

Wrapping 2020 with a subtle depreciation- What’s on the cards for the Rupee in 2021?

Business

Cipla gets final nod from USFDA for multiple sclerosis drug

Updated : September 25, 2020 01:19 PM IST

Drug major Cipla on Friday said it has received final approval from the US health regulator for Dimethyl Fumarate capsules, indicated for the treatment of relapsing forms of multiple sclerosis. The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc’s Tecfidera.

Cipla has received final approval for its abbreviated new drug application (ANDA) for Dimethyl Fumarate DR (delayed release) capsules in the strengths of 120mg, 240mg and 120mg and 240mg from the United States Food and Drug Administration (USFDA), the company said in a regulatory filing.

Quoting IQVIA (IMS Health) data, Cipla said Tecfidera had US sales of approximately USD 3.8 billion for the 12-month period ending July 2020. Shares of Cipla were trading 2.12 percent higher at Rs 748.35 apiece on the BSE.

Also Read: Zydus Cadila gets USFDA nod for multiple sclerosis treatment drug

You May Also Like

COVID-19: 14,256 fresh cases in India; tally at over 1.06 crore

COVID-19: 14,256 fresh cases in India; tally at over 1.06 crore

GoAir offers 1 million seats at Rs 859 each on domestic travel

GoAir offers 1 million seats at Rs 859 each on domestic travel

PNB raises Rs 495 crore via AT-1 bonds

PNB raises Rs 495 crore via AT-1 bonds

Trending on CNBC-TV18

Live TV

recommended for you